IP Library Granted Patent US 7,247,714
Granted Patent B2
US 7,247,714 · App. 10/271,429 · Granted Jul 24, 2007

Protection against oxidative stress and inflammation by a cytoprotective response element

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,247,714
App. No.
10/271,429
Granted
Jul 24, 2007
Kind
B2
Abstract

This invention is in the area of regulatory DNA sequences and their methods of use. Specifically, DNA sequences found in the regulatory region of cytoprotective genes are described that are termed cytoprotective response elements. DNA constructs also are provided that include cytoprotective response elements operably linked to heterologous protein coding sequence, as well as cells and non-human organisms that include the cytoprotective response elements optionally operably linked to a heterologous protein coding sequence, and a method for screening for a compound that increases mRNA or protein regulated by a cytoprotective response element. It has been discovered that the cytoprotective response elements mediate the coordinate activation of certain genes that protect cells from damaging effects of oxidative stress, and that they do so, for example during conditions of hemodynamic shear stress.

Claims (20)

1. An isolated nucleic acid consisting of SEQ ID NO:1.

2. A nucleic acid construct consisting of SEQ ID NO:1, operably linked to a heterologous protein coding sequence.

3. A nucleic acid construct comprising a cytoprotective response element consisting of SEQ ID NO:1.

4. A nucleic acid construct comprising a cytoprotective response element consisting of SEQ ID NO:1 operably linked to a promoter.

5. The construct of claim 4 wherein the promoter is operably linked to a reporter gene.

6. The construct of claim 4 or 5 wherein the promoter is selected from the group consisting of SV40, CMV and TK.

7. The construct of claim 5 wherein the reporter gene is selected from the group consisting of luciferase, CAT, secreted alkaline phosphatase, green fluorescent protein, and human growth hormone.

8. A nucleic acid construct consisting of one to ten cytoprotective response elements wherein the cytoprotective response element is SEQ ID NO:1 that induces the expression of microsomal epoxide hydroxylase.

9. An isolated nucleic acid construct comprising two to ten cytoprotective response elements wherein the cytoprotective response element is SEQ ID NO:1.

10. An isolated nucleic acid construct comprising three to ten cytoprotective response elements wherein the cytoprotective response element is SEQ ID NO:1.

11. The construct of claim 9 wherein the cytoprotective response elements are operably linked to a promoter.

12. The construct of claim 11 wherein the promoter is operably linked to a reporter gene.

13. The construct of claim 11 or 12 wherein the promoter is selected from the group consisting of SV40, CMV and TK.

14. The construct of claim 12 wherein the reporter gene is selected from the group consisting of luciferase, CAT, secreted alkaline phosphatase, green fluorescent protein, and human growth hormone.

15. The construct of claim 10 wherein the cytoprotective response elements are operably linked to a promoter.

16. The construct of claim 15 wherein the promoter is operably linked to a reporter gene.

17. The construct of claim 15 or 16 wherein the promoter is selected from the group consisting of SV40, CMV and TK.

18. The construct of claim 6 , wherein the reporter gene is selected from the group consisting of luciferase, CAT, secreted alkaline phosphatase, green fluorescent protein, and human growth hormone.

19. The construct of claim 13 wherein the reporter gene is selected from the group consisting of luciferase, CAT, secreted alkaline phosphatase, green fluorescent protein, and human growth hormone.

20. The construct of claim 3 , wherein the construct is a vector.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: ATHEROGENICS, INC.
To: CRABTREE ACQUISITION CO, LLC
Reel/Frame 024933/0616 →
CHANGE OF NAME Recorded Sep 3, 2010
From: CRABTREE ACQUISITION CO, LLC
To: SALUTRIA PHARMACEUTICALS LLC
Reel/Frame 024933/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2003
From: KUNSCH, CHARLES; VARNER, SIGNE E.; CHEN, XILIN; LUCHOOMUN, JAYRAZ
To: ATHEROGENICS, INC.
Reel/Frame 013760/0187 →